Home › Funds › Duquesne Family Office LLC › BLTE
Duquesne Family Office LLC position in BLTE
BELITE BIO INC · Health Care
Duquesne Family Office LLC reported holding 106,100 shares of BLTE (BELITE BIO INC) in its Q3 2026 13F filing — a position valued at US$18.0M, representing 0.48% of its reported portfolio and ranking #37 among its reported holdings. Duquesne Family Office LLC has disclosed BLTE holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Duquesne Family Office LLC's BLTE position evolved
Duquesne Family Office LLC first disclosed a stake in BLTE in Q1 2026 at 106,100 shares (US$16.9M). The position peaked in Q3 2026 at 106,100 shares, worth US$18.0M. Across 3 filings, Duquesne Family Office LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 106,100 shares valued at US$18.0M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 106.10K | $16.92M | New |
| Q2 2026 | 106.10K | $16.34M | Hold |
| Q3 2026 | 106.10K | $18.02M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BLTE and 13F data
BLTE (BELITE BIO INC) is a Health Care company. 73 other funds we track also report a position in BLTE — the largest reported positions include Darwin Global Management, Ltd. (US$526.0M), Paradigm Biocapital Advisors LP (US$194.0M), RTW INVESTMENTS, LP (US$121.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BLTE
- Darwin Global Management, Ltd. 3.10M sh · $525.95M · Q3 2026
- Paradigm Biocapital Advisors LP 1.14M sh · $193.96M · Q3 2026
- RTW INVESTMENTS, LP 715.33K sh · $121.48M · Q3 2026
- MAVERICK CAPITAL LTD 609.91K sh · $103.57M · Q3 2026
- EVENTIDE ASSET MANAGEMENT, LLC 390.83K sh · $66.37M · Q3 2026
- Maverick Capital 396.31K sh · $61.03M · Q2 2026
- Affinity Asset Advisors, LLC 242.09K sh · $41.11M · Q3 2026
- Logos Global Management LP 200.00K sh · $33.96M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 190.00K sh · $32.27M · Q3 2026
- MPM BioImpact LLC 133.39K sh · $22.65M · Q3 2026
- Patient Square Capital LP 131.70K sh · $22.37M · Q3 2026
- GREAT POINT PARTNERS LLC 75.00K sh · $12.74M · Q3 2026
More on Duquesne Family Office LLC
FAQ
How long has Duquesne Family Office LLC held BLTE?
Duquesne Family Office LLC has disclosed BLTE holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Duquesne Family Office LLC's current position in BLTE?
As of Q3 2026, Duquesne Family Office LLC holds 106.10K shares of BLTE (BELITE BIO INC), valued at $18.02M, representing 0.48% of its reported portfolio and ranking #37.
Has Duquesne Family Office LLC been buying or selling BLTE?
In the latest 13F filing (Q3 2026), Duquesne Family Office LLC held unchanged its position in BLTE. The position peaked in Q3 2026 at 106.10K shares.
Which other funds hold BLTE?
Other major institutional holders of BLTE include Darwin Global Management, Ltd., Paradigm Biocapital Advisors LP, RTW INVESTMENTS, LP, among 73 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.